DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for coagulation protein disease — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCoagulation protein disease maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedXimelagatranThrombin inhibitor
Structures already discussed alongside coagulation protein disease in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
coagulation factor VII (F7) — F7 is one of the genes in this disease's Open Targets module — part of the target space DeCure's repurposing candidates point at. The protein backbone is drawn as a cartoon. The structure has (2r)-2-hydroxy-n-[[3-[5-hydroxy-4-(1h-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-methylbutanamide bound in it, shown as sticks.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5PAG · 1.36 Å · ligand (2R)-2-hydroxy-N-[[3-[5-hydroxy-4-(1H-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-methylbutanamide (7YJ). Experimental structure, not a prediction.
What the evidence adds up to
A 2017 case report describes a patient who developed an acquired factor V inhibitor after coronary artery bypass grafting and cephalosporin treatment, presenting with severe cerebral haemorrhage. The patient received corticosteroids, intravenous immunoglobulins, rituximab, cyclophosphamide, and recombinant factor VIIa, and achieved full recovery despite a poor initial prognosis. The authors note there are no clear guidelines for acquired coagulation inhibitor treatment and that this combination of multiple agents, including rituximab, was unique to the case.
A 2004 review of the ESTEEM trial discusses ximelagatran, an oral direct thrombin inhibitor, for long-term anticoagulation in coronary artery disease. It states ximelagatran has predictable pharmacokinetics, can be used at a fixed dose without coagulation monitoring, and has a low potential for drug and food interactions. A 2005 report on a manufacturer-funded randomised trial confirms ximelagatran (36 mg twice daily) was shown to be effective for long-term secondary prevention of venous thromboembolism compared with standard therapy.
A 2020 review of blood coagulation studies notes that congenital and acquired coagulation disorders remain an acute clinical problem, but does not report any new treatment outcomes or drug-specific data. It summarises modern understanding of the coagulation system's structure and regulation.
What is still missing: no randomised controlled trial data exist for the multi-agent regimen used in the factor V inhibitor case; ximelagatran is no longer marketed; no large-scale, adequately funded trials have been designed to test specific drug combinations for acquired coagulation factor inhibitors, and patient stratification by inhibitor type and bleeding severity remains unaddressed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Balkan Medical Journal · 2017 · 3 citations · open access
Successful Outcome of Severe Intra-cerebral Bleeding Associated with Acquired Factor V Inhibition: Utilization of Multiple Therapeutic Agents
AbstractBACKGROUND: Acquired coagulation factor inhibitors are antibodies that either inhibit activity or increase the clearance of a clotting factor and lead to an increased risk of bleeding. Most of the time, the disorder is attributed to factor VIII inhibition (acquired haemophilia A); however, other coagulation factors could also be implicated. CASE REPORT: Herein, we report an interesting case of a patient who underwent coronary artery bypass grafting and received antibiotic treatment after surgery with third generation cephalosporin. A month later, he presented with extreme bleeding diathesis and cerebral haemorrhage. Following a thorough clinical and laboratory investigation, an acquired factor V inhibitor was diagnosed. The patient received treatment with corticosteroids, intravenous immunoglobulins, anti-CD20 monoclonal antibodies (rituximab), cyclophosphamide and recombinant factor VIIa. Finally, despite the poor initial prognosis, the patient managed to achieve a full recovery. CONCLUSION: As there are no clear guidelines on acquired coagulation inhibitor treatment, reports of such cases could offer insight for future therapy choices. The case was unique because the treatment regimen included a combination of multiple therapeutic agents including rituximab.
Pediatric Hematology/Oncology and Immunopathology · 2020 · 3 citations · open access
Current trends in blood coagulation studies
AbstractBlood coagulation occurs in flow or stasis conditions, it involves components of cell hemostasis and enzymatic cascades of reactions; it serves to stop bleeding yet it can lead to life-threatening blood thrombi. Despite the fact that a complete list of coagulation proteins was well known for decades, in recent years numerous facts has accumulated about its structure and regulation. All that has led to the creation of new methods for diagnosing of blood coagulation disorders and methods for their correction. Congenital and acquired coagulation disorders are still an acute clinical problem. This review shows modern ideas about the structure and functioning of the blood coagulation system in various conditions.
European Heart Journal Supplements · 2004 · 1 citations · open access
Oral direct thrombin inhibition for anticoagulation in coronary artery disease ? focus on the ESTEEM trial
AbstractLong-term treatment with anticoagulation agents in combination with aspirin can be beneficial for the prevention of recurrent thrombotic events, although the limitations of current agents make their use far from ideal. In contrast, the oral direct thrombin inhibitor, ximelagatran, has considerable therapeutic potential in this disease area because it has predictable pharmacokinetics and dynamics and therefore can be used at a fixed dose, does not require coagulation monitoring and has a low potential for drug and food interactions.
AbstractXimelagatran, an oral direct thrombin inhibitor that does not require coagulation monitoring, has been shown to be effective for long-term secondary prevention of venous thromboembolism (VTE; Journal Watch Cardiology Feb 13 2004). Now, researchers have conducted a multinational, manufacturer-funded, randomized trial of ximelagatran (36 mg twice daily) versus standard therapy …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
